MAPT and supranuclear palsy, progressive, 1: Surprisingly though, no significant association was found in that study between level of [18F]-PI-2620 in vivo retention and disease duration or clinical severity of symptoms arguing against the reliability of this tracer to accurately detect and track the expected progressive accumulation of tau pathology in PSP.